827 related articles for article (PubMed ID: 30488542)
1. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.
Jonstam K; Swanson BN; Mannent LP; Cardell LO; Tian N; Wang Y; Zhang D; Fan C; Holtappels G; Hamilton JD; Grabher A; Graham NMH; Pirozzi G; Bachert C
Allergy; 2019 Apr; 74(4):743-752. PubMed ID: 30488542
[TBL] [Abstract][Full Text] [Related]
2. Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab.
Kariyawasam HH
Expert Rev Clin Immunol; 2020 Dec; 16(12):1115-1125. PubMed ID: 33148074
[No Abstract] [Full Text] [Related]
3. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial.
Bachert C; Mannent L; Naclerio RM; Mullol J; Ferguson BJ; Gevaert P; Hellings P; Jiao L; Wang L; Evans RR; Pirozzi G; Graham NM; Swanson B; Hamilton JD; Radin A; Gandhi NA; Stahl N; Yancopoulos GD; Sutherland ER
JAMA; 2016 Feb; 315(5):469-79. PubMed ID: 26836729
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
De Prado Gomez PharmD MSc L; Khan Mbbs Mph AH; Peters Md AT; Bachert Md PhD C; Wagenmann Md M; Heffler Md PhD E; Hopkins BMBCh C; Hellings Md PhD PW; Zhang PhD M; Xing PhD J; Rowe Md P; Jacob-Nara Md Mph DHSc JA
Am J Rhinol Allergy; 2022 Nov; 36(6):788-795. PubMed ID: 35837739
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.
Hamilton JD; Harel S; Swanson BN; Brian W; Chen Z; Rice MS; Amin N; Ardeleanu M; Radin A; Shumel B; Ruddy M; Patel N; Pirozzi G; Mannent L; Graham NMH
Clin Exp Allergy; 2021 Jul; 51(7):915-931. PubMed ID: 34037993
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab: Clinical Efficacy of Blocking IL-4/IL-13 Signalling in Chronic Rhinosinusitis with Nasal Polyps.
Kariyawasam HH; James LK; Gane SB
Drug Des Devel Ther; 2020; 14():1757-1769. PubMed ID: 32440101
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52.
Bachert C; Khan AH; Lee SE; Hopkins C; Peters AT; Fokkens W; Praestgaard A; Radwan A; Nash S; Jacob-Nara JA; Deniz Y; Rowe PJ
Int Forum Allergy Rhinol; 2024 Mar; 14(3):668-678. PubMed ID: 37548085
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
Laidlaw TM; Bachert C; Amin N; Desrosiers M; Hellings PW; Mullol J; Maspero JF; Gevaert P; Zhang M; Mao X; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
Ann Allergy Asthma Immunol; 2021 May; 126(5):584-592.e1. PubMed ID: 33465455
[TBL] [Abstract][Full Text] [Related]
10. Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps.
Hoy SM
Drugs; 2020 May; 80(7):711-717. PubMed ID: 32240527
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis.
Bachert C; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Joish VN; Chao J; Mannent LP; Amin N; Abbe A; Taniou C; Fan C; Pirozzi G; Graham NMH; Mahajan P; Staudinger H; Khan A
Allergy; 2020 Jan; 75(1):148-157. PubMed ID: 31306495
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.
Bachert C; Zinreich SJ; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Amin N; Joish VN; Fan C; Zhang D; Staudinger H; Pirozzi G; Graham NMH; Khan A; Mannent LP
Rhinology; 2020 Feb; 58(1):10-17. PubMed ID: 31671432
[TBL] [Abstract][Full Text] [Related]
13. Global influence of dupilumab on Quality of Life in a severe asthma patient with T2 multimorbidities: a case report on atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.
Colque-Bayona M; Hernández-Cano N; Tomás-Pérez M; Caballero T; Quirce S; Domínguez-Ortega J
J Asthma; 2024 Jul; 61(7):762-765. PubMed ID: 38152869
[TBL] [Abstract][Full Text] [Related]
14. Th2 cytokines orchestrate the secretion of MUC5AC and MUC5B in IL-5-positive chronic rhinosinusitis with nasal polyps.
Zhang Y; Derycke L; Holtappels G; Wang XD; Zhang L; Bachert C; Zhang N
Allergy; 2019 Jan; 74(1):131-140. PubMed ID: 29802623
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab in the treatment of chronic rhinosinusitis with nasal polyposis.
Boyle JV; Lam K; Han JK
Immunotherapy; 2020 Feb; 12(2):111-121. PubMed ID: 32075470
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
Mullol J; Laidlaw TM; Bachert C; Mannent LP; Canonica GW; Han JK; Maspero JF; Picado C; Daizadeh N; Ortiz B; Li Y; Ruddy M; Laws E; Amin N
Allergy; 2022 Apr; 77(4):1231-1244. PubMed ID: 34459002
[TBL] [Abstract][Full Text] [Related]
17. Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results.
Bachert C; Laidlaw TM; Cho SH; Mullol J; Swanson BN; Naimi S; Classe M; Harel S; Jagerschmidt A; Laws E; Ruddy M; Praestgaard A; Amin N; Mannent LP
Ann Otol Rhinol Laryngol; 2023 Dec; 132(12):1649-1661. PubMed ID: 37322842
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab (Dupixent
Jansen F; Becker B; Eden JK; Breda PC; Hot A; Oqueka T; Betz CS; Hoffmann AS
Eur Arch Otorhinolaryngol; 2023 Apr; 280(4):1741-1755. PubMed ID: 36242612
[TBL] [Abstract][Full Text] [Related]
19. Conjunctivitis in dupilumab clinical trials.
Akinlade B; Guttman-Yassky E; de Bruin-Weller M; Simpson EL; Blauvelt A; Cork MJ; Prens E; Asbell P; Akpek E; Corren J; Bachert C; Hirano I; Weyne J; Korotzer A; Chen Z; Hultsch T; Zhu X; Davis JD; Mannent L; Hamilton JD; Teper A; Staudinger H; Rizova E; Pirozzi G; Graham NMH; Shumel B; Ardeleanu M; Wollenberg A
Br J Dermatol; 2019 Sep; 181(3):459-473. PubMed ID: 30851191
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis.
Peters AT; Wagenmann M; Bernstein JA; Khan AH; Nash S; Jacob-Nara JA; Siddiqui S; Rowe PJ; Deniz Y
Allergy Asthma Proc; 2023 Jul; 44(4):265-274. PubMed ID: 37480206
[No Abstract] [Full Text] [Related]
[Next] [New Search]